DAILYPEPTIDE GUIDE
Unstandardized combination

CJC-1295 + ipamorelin

CJC-1295 + Ipamorelin

Uncertain or Concerning

Video guide

Video guides are coming soon.

Identity

Commercial or common name

CJC-1295 + ipamorelin. This name is not standardized.

Variants

Reported formulation variants

  • DAC and no-DAC versions of CJC-1295 are marketed under the same stack name
Combination evidence

What the combination shows

No adequate human combination evidence was identified in the static MVP review. Component-level findings do not transfer to the combination.

Regulatory

Status

Unapproved / RUO. No approval is implied by use of a commercial or community name.

Human research

Combination trial status

No validated human combination trial identified

Quality

Stability and compatibility

Compatibility, sterility and stability are not established across marketed variants

Claims

Common marketing claims

  • Growth hormone release
  • Body composition
  • Recovery
Evidence-based conclusion

Bottom line

This named stack should be evaluated as an unstandardized combination. It does not inherit the evidence score of its strongest component.

Individual component evidence

Experimental / RUOVerification pending

CJC-1295

CJC-1295 with DAC

An investigational growth-hormone-releasing hormone analogue.

Tier 3Unapproved / RUO
Experimental / RUOVerification pending

Ipamorelin

Ipamorelin acetate

A research peptide that stimulates growth-hormone release.

Tier 3Unapproved / RUO